| Patients | EGFR tested | p-value# | |||
| Total n | 85 | 60 | |||
| Age yrs | 59.8 (28.3–87.7) | 61.4 (39.1–87.7) | 0.070+ | ||
| Sex | 0.060 | ||||
| Females | 44 (52) | 35 (58) | |||
| Males | 41 (48) | 25 (42) | |||
| Smoking | 0.169 | ||||
| Nonsmokers | 63 (74) | 47 (78) | |||
| Former/current smokers | 22 (26) | 13 (22) | |||
| ECOG PS | 0.055 | ||||
| 0–1 | 63 (74) | 48 (80) | |||
| 2–4 | 22 (26) | 12 (20) | |||
| Tumour type | 0.577§ | ||||
| Nonadenocarcinoma | 4 (5) | 2 (3) | |||
| Adenocarcinoma | 81 (95) | 58 (97) | |||
| Distant metastasis | |||||
| Bone | 54 (64) | 37 (62) | 0.580 | ||
| Brain | 31 (37) | 22 (37) | 0.954 | ||
| Liver | 23 (27) | 17 (28) | 0.682 | ||
| Adrenal gland | 8 (9) | 8 (13) | 0.098§ | ||
| Others¶ | 12 (14) | 7 (12) | 0.315 | ||
Data are presented as n (%) or mean (range), unless otherwise stated. EGFR: epidermal growth factor receptor; ECOG PS: Eastern Cooperative Oncology Group performance status. #: comparison between the groups with and without EGFR sequencing; ¶: five spleen, one peritoneal, two cervical lymph nodes, three intra-abdominal lymphoadenopathy and one kidney; +: t-test. §: Fisher’s exact test.